The study published in Science Translational Medicine found that tissue stiffening in the breasts of obese women can drive the development of malignant disease.
Scientists at Cornell University have uncovered a mechanism that drives breast tumorigenesis in obese women. Obesity, the authors explain, causes fibrotic remodeling of the fat tissue; these structural changes promoted the growth of premalignant as well as malignant breast cells. Irrespective of whether the weight gain was genetic or diet-related, mouse models developed by the researchers showed stiffening of mammary tissue, which promoted overgrowth of cells.
Stromal changes caused by obesity was the primary cause of these changes, the authors hypothesized in the paper published in Science Translational Medicine. The authors found that obese mice produced a significantly greater number of myofibroblasts, which deposited a stiffer extracellular matrix, and the resulting mechanosignaling, the authors claim, stimulated the malignant potential of breast cancer cells. To evaluate whether weight loss could reverse tissue stiffening, the authors placed the mice on a calorie-restricted diet and discovered reduced myofibroblasts and a hint of reduction in tissue stiffening.
These results have a wider implication, especially for women with dense breast tissue, which is associated with a higher risk of developing breast cancer when detected on a screening mammogram. According to the authors, fat can mask the density readings and necessitate high-resolution imaging in these women. While the authors hypothesize that weight loss could reduce the risk of developing breast cancer, studies that directly attempt to address the hypothesis are essential.
Read more at MedicalXpress.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More